Schroder Investment Management Group
IOVA icon

Schroder Investment Management Group’s Iovance Biotherapeutics IOVA Stock Holding History

Schroder Investment Management Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-897,354
Closed -$1.54M – 1222
2025
Q2 		$1.54M Buy
897,354
+394,791
+79% +$982K ﹤0.01% 944
2025
Q1 		$1.79M Buy
502,563
+259,267
+107% +$1.34M ﹤0.01% 922
2024
Q4 		$1.74M Hold
243,296
– – ﹤0.01% 943
2024
Q3 		$2.34M Sell
243,296
-525,864
-68% -$4.98M ﹤0.01% 916
2024
Q2 		$6.17M Buy
769,160
+438,377
+133% +$4.7M 0.01% 735
2024
Q1 		$4.9M Buy
330,783
+6,047
+2% +$70.4K 0.01% 784
2023
Q4 		$2.64M Buy
+324,736
New +$1.7M ﹤0.01% 868

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Schroder Investment Management Group's IOVA Position: Q3 2025 in Review

Schroder Investment Management Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 897,354 shares — an estimated $1.54M sold.

Schroder Investment Management Group first reported a position in IOVA in Q4 2023 and held it in 7 quarters. The position peaked at $6.17M in Q2 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Schroder Investment Management Group reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 897,354 Iovance Biotherapeutics shares in Q3 2025, an estimated $1.54M.
  • Schroder Investment Management Group first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 7 quarters.
  • Schroder Investment Management Group's Iovance Biotherapeutics position peaked at $6.17M in Q2 2024.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Schroder Investment Management Group's 13F filing for Q3 2025, filed 13 Nov 2025.